Mustang BioInc.
Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes(Mustang Bio, Inc.)은 EGFR 표적 세포·유전자 치료로, Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting CSF-1R and PD-1 inhibited the CSF1/CSF-1R and PD-1/PD-L1 pathway. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel IL-2 suppressive agent.
EGFR
Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia
Recruiting
NK cell recognition via the "missing-self" response
retroviral therapy (ART) and evade immune clearance
humanized mouse models
novel IL-2 suppressive agent
targeting CSF-1R and PD-1 inhibited the CSF1/CSF-1R and PD-1/PD-L1 pathway
T-cell homeostasis imbalance, B-cell functional exhaustion, and abnormal activation
apoptosis profiles, and serum cytokine levels
biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to
escape, T-cell exhaustion, and the limited efficacy of CAR-T cells in acute myeloid leukemia (AML) and T-cell leukemias still
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Mustang BioInc.
Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes(Mustang Bio, Inc.)은 EGFR 표적 세포·유전자 치료로, Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia 영역에서 개발·상용화 중입니다. 작용기전: targeting CSF-1R and PD-1 inhibited the CSF1/CSF-1R and PD-1/PD-L1 pathway. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel IL-2 suppressive agent.
EGFR
Adult Acute Myeloid Leukemia in Remission; Acute Biphenotypic Leukemia
Recruiting
NK cell recognition via the "missing-self" response
retroviral therapy (ART) and evade immune clearance
humanized mouse models
novel IL-2 suppressive agent
targeting CSF-1R and PD-1 inhibited the CSF1/CSF-1R and PD-1/PD-L1 pathway
T-cell homeostasis imbalance, B-cell functional exhaustion, and abnormal activation
apoptosis profiles, and serum cytokine levels
biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to
escape, T-cell exhaustion, and the limited efficacy of CAR-T cells in acute myeloid leukemia (AML) and T-cell leukemias still
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.